Intriguingly, the sodium–glucose co‐transporter 2 (SGLT2) inhibitors, which are an antidiabetic drug class that have been demonstrated to improve cardiovascular outcomes in people with T2D, often lead to increases in circulating ketone levels (Lopaschuk & Dyck, 2023; Puchalska & Crawford, 2017). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.